How much funding has Exeliom Biosciences raised?

Exeliom Biosciences has raised $37.6M in total funding, most recently a Series A round.

Who are Exeliom Biosciences's investors?

Exeliom Biosciences's investors include Crescent Enterprises, Auriga, UI Investissement.

When was Exeliom Biosciences founded?

Exeliom Biosciences was founded in 2016.

Where is Exeliom Biosciences headquartered?

Exeliom Biosciences is headquartered in Dijon, France.

What industry is Exeliom Biosciences in?

Exeliom Biosciences operates in Biotech, Healthcare.

How many employees does Exeliom Biosciences have?

Exeliom Biosciences has 1-10 employees.

Exeliom Biosciences

Crossing the next frontier, to give you a fair chance to fight

Dijon, France · Founded 2016 · $37.6M raised

Biotech

Healthcare

Headquarters: Dijon
Employees: 1–10
Founded: 2016
Business Model: B2B

Website: exeliombio.com
Total Funding: $37.6M
Last Round: $26.0M Series AJun 2023
Rounds: 2

About

Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation, with a lead candidate EXL01 — a first-in-class innate immune conditioner derived from Faecalibacterium prausnitzii that targets the NOD2-CARD9 pathway to restore myeloid support for anti-tumor immunity. Founded in 2016 and headquartered in Dijon, France, the company has progressed EXL01 from discovery through multiple Phase 2 randomized clinical trials spanning gastric cancer, renal cell carcinoma, Crohn's disease, and recurrent C. difficile infections. Built on a capital-efficient model with a core team of approximately 10 employees, Exeliom has earned Bpifrance 'Deeptech' and 'I-Lab' designations as well as EIC Accelerator funding from the European Innovation Council.

Summary

Exeliom Biosciences is a Biotech company based in Dijon, France, founded in 2016. It has raised $37.6M in total across 2 rounds, most recently a $26.0M Series A round in Jun 2023. Investors include Crescent Enterprises, Auriga and UI Investissement.